+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market 2024-2028

  • PDF Icon

    Report

  • 164 Pages
  • October 2023
  • Region: Global
  • TechNavio
  • ID: 5574347
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The HER2 (human epidermal growth factor receptor 2) inhibitors market is forecasted to grow by USD 11066.53 mn during 2023-2028, accelerating at a CAGR of 9.94% during the forecast period. The report on the HER2 (human epidermal growth factor receptor 2) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of breast cancer and gastric cancer, advancements in R&D, and growing awareness about breast cancer.

The HER2 (human epidermal growth factor receptor 2) inhibitors market is segmented as below:

By Product

  • Monotherapy
  • Combination therapy

By Distribution Channel

  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the patient assistance programs as one of the prime reasons driving the HER2 (human epidermal growth factor receptor 2) inhibitors market growth during the next few years. Also, introduction of new diagnostics for breast cancer and strategic alliances will lead to sizable demand in the market.

The report on the HER2 (human epidermal growth factor receptor 2) inhibitors market covers the following areas:

  • HER2 (human epidermal growth factor receptor 2) inhibitors market sizing
  • HER2 (human epidermal growth factor receptor 2) inhibitors market forecast
  • HER2 (human epidermal growth factor receptor 2) inhibitors market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 (human epidermal growth factor receptor 2) inhibitors market vendors that include Amgen Inc., AryoGen Pharmed, AstraZeneca Plc, Biocon Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., JSC BIOCAD, MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Samsung Biologics Co. Ltd., Shanghai Henlius Biotech Inc., Viatris Inc., and Celltrion Healthcare Co. Ltd.. Also, the HER2 (human epidermal growth factor receptor 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global HER2 (human epidermal growth factor receptor 2) inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global her2 (human epidermal growth factor receptor 2) inhibitors market 2018 - 2022 ($ million)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Monotherapy - Market size and forecast 2023-2028
Exhibit 34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
6.4 Combination therapy - Market size and forecast 2023-2028
Exhibit 38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Product
Exhibit 42: Market opportunity by Product ($ million)
Exhibit 43: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 46: Chart on Comparison by Distribution Channel
Exhibit 47: Data Table on Comparison by Distribution Channel
7.3 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 48: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 49: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 60: Market opportunity by Distribution Channel ($ million)
Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 Canada - Market size and forecast 2023-2028
Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Amgen Inc.
Exhibit 111: Amgen Inc. - Overview
Exhibit 112: Amgen Inc. - Product/Service
Exhibit 113: Amgen Inc. - Key offerings
12.4 AstraZeneca Plc
Exhibit 114: AstraZeneca Plc - Overview
Exhibit 115: AstraZeneca Plc - Product/Service
Exhibit 116: AstraZeneca Plc - Key news
Exhibit 117: AstraZeneca Plc - Key offerings
12.5 Biocon Ltd.
Exhibit 118: Biocon Ltd. - Overview
Exhibit 119: Biocon Ltd. - Business segments
Exhibit 120: Biocon Ltd. - Key offerings
Exhibit 121: Biocon Ltd. - Segment focus
12.6 Boehringer Ingelheim International GmbH
Exhibit 122: Boehringer Ingelheim International GmbH - Overview
Exhibit 123: Boehringer Ingelheim International GmbH - Business segments
Exhibit 124: Boehringer Ingelheim International GmbH - Key news
Exhibit 125: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 126: Boehringer Ingelheim International GmbH - Segment focus
12.7 Bristol Myers Squibb Co.
Exhibit 127: Bristol Myers Squibb Co. - Overview
Exhibit 128: Bristol Myers Squibb Co. - Product/Service
Exhibit 129: Bristol Myers Squibb Co. - Key news
Exhibit 130: Bristol Myers Squibb Co. - Key offerings
12.8 Celltrion Healthcare Co. Ltd.
Exhibit 131: Celltrion Healthcare Co. Ltd. - Overview
Exhibit 132: Celltrion Healthcare Co. Ltd. - Product/Service
Exhibit 133: Celltrion Healthcare Co. Ltd. - Key offerings
12.9 Dr Reddys Laboratories Ltd.
Exhibit 134: Dr Reddys Laboratories Ltd. - Overview
Exhibit 135: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 136: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 137: Dr Reddys Laboratories Ltd. - Segment focus
12.10 Eli Lilly and Co.
Exhibit 138: Eli Lilly and Co. - Overview
Exhibit 139: Eli Lilly and Co. - Product/Service
Exhibit 140: Eli Lilly and Co. - Key news
Exhibit 141: Eli Lilly and Co. - Key offerings
12.11 F. Hoffmann La Roche Ltd.
Exhibit 142: F. Hoffmann La Roche Ltd. - Overview
Exhibit 143: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 144: F. Hoffmann La Roche Ltd. - Key news
Exhibit 145: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 146: F. Hoffmann La Roche Ltd. - Segment focus
12.12 Intas Pharmaceuticals Ltd.
Exhibit 147: Intas Pharmaceuticals Ltd. - Overview
Exhibit 148: Intas Pharmaceuticals Ltd. - Product/Service
Exhibit 149: Intas Pharmaceuticals Ltd. - Key offerings
12.13 Merck KGaA
Exhibit 150: Merck KGaA - Overview
Exhibit 151: Merck KGaA - Business segments
Exhibit 152: Merck KGaA - Key news
Exhibit 153: Merck KGaA - Key offerings
Exhibit 154: Merck KGaA - Segment focus
12.14 Novartis AG
Exhibit 155: Novartis AG - Overview
Exhibit 156: Novartis AG - Business segments
Exhibit 157: Novartis AG - Key offerings
Exhibit 158: Novartis AG - Segment focus
12.15 Pfizer Inc.
Exhibit 159: Pfizer Inc. - Overview
Exhibit 160: Pfizer Inc. - Product/Service
Exhibit 161: Pfizer Inc. - Key news
Exhibit 162: Pfizer Inc. - Key offerings
12.16 Puma Biotechnology Inc.
Exhibit 163: Puma Biotechnology Inc. - Overview
Exhibit 164: Puma Biotechnology Inc. - Product/Service
Exhibit 165: Puma Biotechnology Inc. - Key offerings
12.17 Viatris Inc.
Exhibit 166: Viatris Inc. - Overview
Exhibit 167: Viatris Inc. - Business segments
Exhibit 168: Viatris Inc. - Key news
Exhibit 169: Viatris Inc. - Key offerings
Exhibit 170: Viatris Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 171: Inclusions checklist
Exhibit 172: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 173: Currency conversion rates for US$
13.4 Research methodology
Exhibit 174: Research methodology
Exhibit 175: Validation techniques employed for market sizing
Exhibit 176: Information sources
13.5 List of abbreviations
Exhibit 177: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global her2 (human epidermal growth factor receptor 2) inhibitors market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Product - Market share 2023-2028 (%)
Exhibits 31: Data Table on Product - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Product
Exhibits 33: Data Table on Comparison by Product
Exhibits 34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
Exhibits 42: Market opportunity by Product ($ million)
Exhibits 43: Data Table on Market opportunity by Product ($ million)
Exhibits 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 46: Chart on Comparison by Distribution Channel
Exhibits 47: Data Table on Comparison by Distribution Channel
Exhibits 48: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 49: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 50: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 51: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 60: Market opportunity by Distribution Channel ($ million)
Exhibits 61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 65: Chart on Geographic comparison
Exhibits 66: Data Table on Geographic comparison
Exhibits 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 103: Market opportunity By Geographical Landscape ($ million)
Exhibits 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 105: Impact of drivers and challenges in 2023 and 2028
Exhibits 106: Overview on Criticality of inputs and Factors of differentiation
Exhibits 107: Overview on factors of disruption
Exhibits 108: Impact of key risks on business
Exhibits 109: Vendors covered
Exhibits 110: Matrix on vendor position and classification
Exhibits 111: Amgen Inc. - Overview
Exhibits 112: Amgen Inc. - Product/Service
Exhibits 113: Amgen Inc. - Key offerings
Exhibits 114: AstraZeneca Plc - Overview
Exhibits 115: AstraZeneca Plc - Product/Service
Exhibits 116: AstraZeneca Plc - Key news
Exhibits 117: AstraZeneca Plc - Key offerings
Exhibits 118: Biocon Ltd. - Overview
Exhibits 119: Biocon Ltd. - Business segments
Exhibits 120: Biocon Ltd. - Key offerings
Exhibits 121: Biocon Ltd. - Segment focus
Exhibits 122: Boehringer Ingelheim International GmbH - Overview
Exhibits 123: Boehringer Ingelheim International GmbH - Business segments
Exhibits 124: Boehringer Ingelheim International GmbH - Key news
Exhibits 125: Boehringer Ingelheim International GmbH - Key offerings
Exhibits 126: Boehringer Ingelheim International GmbH - Segment focus
Exhibits 127: Bristol Myers Squibb Co. - Overview
Exhibits 128: Bristol Myers Squibb Co. - Product/Service
Exhibits 129: Bristol Myers Squibb Co. - Key news
Exhibits 130: Bristol Myers Squibb Co. - Key offerings
Exhibits 131: Celltrion Healthcare Co. Ltd. - Overview
Exhibits 132: Celltrion Healthcare Co. Ltd. - Product/Service
Exhibits 133: Celltrion Healthcare Co. Ltd. - Key offerings
Exhibits 134: Dr Reddys Laboratories Ltd. - Overview
Exhibits 135: Dr Reddys Laboratories Ltd. - Business segments
Exhibits 136: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits 137: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits 138: Eli Lilly and Co. - Overview
Exhibits 139: Eli Lilly and Co. - Product/Service
Exhibits 140: Eli Lilly and Co. - Key news
Exhibits 141: Eli Lilly and Co. - Key offerings
Exhibits 142: F. Hoffmann La Roche Ltd. - Overview
Exhibits 143: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 144: F. Hoffmann La Roche Ltd. - Key news
Exhibits 145: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 146: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 147: Intas Pharmaceuticals Ltd. - Overview
Exhibits 148: Intas Pharmaceuticals Ltd. - Product/Service
Exhibits 149: Intas Pharmaceuticals Ltd. - Key offerings
Exhibits 150: Merck KGaA - Overview
Exhibits 151: Merck KGaA - Business segments
Exhibits 152: Merck KGaA - Key news
Exhibits 153: Merck KGaA - Key offerings
Exhibits 154: Merck KGaA - Segment focus
Exhibits 155: Novartis AG - Overview
Exhibits 156: Novartis AG - Business segments
Exhibits 157: Novartis AG - Key offerings
Exhibits 158: Novartis AG - Segment focus
Exhibits 159: Pfizer Inc. - Overview
Exhibits 160: Pfizer Inc. - Product/Service
Exhibits 161: Pfizer Inc. - Key news
Exhibits 162: Pfizer Inc. - Key offerings
Exhibits 163: Puma Biotechnology Inc. - Overview
Exhibits 164: Puma Biotechnology Inc. - Product/Service
Exhibits 165: Puma Biotechnology Inc. - Key offerings
Exhibits 166: Viatris Inc. - Overview
Exhibits 167: Viatris Inc. - Business segments
Exhibits 168: Viatris Inc. - Key news
Exhibits 169: Viatris Inc. - Key offerings
Exhibits 170: Viatris Inc. - Segment focus
Exhibits 171: Inclusions checklist
Exhibits 172: Exclusions checklist
Exhibits 173: Currency conversion rates for US$
Exhibits 174: Research methodology
Exhibits 175: Validation techniques employed for market sizing
Exhibits 176: Information sources
Exhibits 177: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global HER2 (human epidermal growth factor receptor 2) inhibitors market: Amgen Inc., AryoGen Pharmed, AstraZeneca Plc, Biocon Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., JSC BIOCAD, MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Samsung Biologics Co. Ltd., Shanghai Henlius Biotech Inc., Viatris Inc., and Celltrion Healthcare Co. Ltd..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is patient assistance programs.'

According to the report, one of the major drivers for this market is the high prevalence of breast cancer and gastric cancer.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen Inc.
  • AryoGen Pharmed
  • AstraZeneca Plc
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Intas Pharmaceuticals Ltd.
  • JSC BIOCAD
  • MacroGenics Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • Samsung Biologics Co. Ltd.
  • Shanghai Henlius Biotech Inc.
  • Viatris Inc.
  • Celltrion Healthcare Co. Ltd.

Related Topics

Related Reports

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (Her2- Breast Cancer) - Global Clinical Trials Review, 2024 - Product Image

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (Her2- Breast Cancer) - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 1264 Pages
  • Global
From
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 180 Pages
  • Global
From
Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report and Forecast 2024-2032 - Product Image

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2024 - Product Image

Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.